- Conditions
- Hereditary Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 73
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
- Interventions
- Egg oral immunotherapy, Control Group
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Allergy, Immunoglobulin E-Mediated Allergic Disorder
- Interventions
- Total Immunoglobulin E, Obtained From Fingerstick Sample
- Diagnostic Test
- Lead sponsor
- Kenota Inc.
- Industry
- Eligibility
- Up to 80 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Saint Paul, Minnesota • Chapel Hill, North Carolina • Virginia Beach, Virginia
- Conditions
- Atopic Dermatitis, Type 1 Hypersensitivity
- Interventions
- STMC-103H, Placebo
- Biological
- Lead sponsor
- Siolta Therapeutics, Inc.
- Industry
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 283 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Type I Hypersensitivity
- Interventions
- Ragweed MATA MPL
- Biological
- Lead sponsor
- Allergy Therapeutics
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 993 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 59
- States / cities
- Waterbury, Connecticut • Atlanta, Georgia • Conyers, Georgia + 47 more
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms
- Interventions
- ThermoDox
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Melanoma (Skin)
- Interventions
- reverse transcriptase-polymerase chain reaction, sentinel lymph node biopsy
- Genetic · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
- Interventions
- Topotecan, Gefitinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
- Interventions
- Sparsentan
- Drug
- Lead sponsor
- Travere Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
- Conditions
- HIV Infections
- Interventions
- gp160 Vaccine (MicroGeneSys)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- gp160 Vaccine (Immuno-AG), gp160 Vaccine (MicroGeneSys)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 4
- States / cities
- Palo Alto, California • San Jose, California • San Mateo, California + 1 more
- Conditions
- Hypersensitivity, Immediate, Atopic Hypersensitivity
- Interventions
- Carbon Black, Diesel Exhaust Particles, Fine Concentrated Ambient Particles, Ultrafine Concentrated Ambient Particles, Saline
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Atopic Immunoglobulin E-Mediated Allergic Disorder
- Interventions
- STMC-103H, Placebo
- Biological
- Lead sponsor
- Siolta Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Stockton, California • Tustin, California
- Conditions
- Glioblastoma
- Interventions
- pH MRI based resection of GBM
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- West Los Angeles, California
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2001
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
- Conditions
- Type I Hypersensitivity
- Interventions
- Grass MATA MPL
- Biological
- Lead sponsor
- Allergy Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
- Interventions
- ADX-324 Dose Level 1, ADX-324 Dose Level 2
- Drug
- Lead sponsor
- ADARx Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 15
- States / cities
- Litchfield Park, Arizona • Little Rock, Arkansas • San Diego, California + 12 more
- Conditions
- Angioedema, Hereditary, Types I and II
- Interventions
- KVD824, Placebo to KVD824
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more
- Conditions
- Type I Hypersensitivity
- Interventions
- RagweedMATAMPL
- Biological
- Lead sponsor
- Allergy Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Novi, Michigan • Minneapolis, Minnesota • Asheville, North Carolina + 1 more
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant low dose, Deucrictibant high dose, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
- Conditions
- Hereditary Angioedema
- Interventions
- KVD900 600 mg, KVD900 300 mg
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
- Conditions
- Cancer
- Interventions
- DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
- Genetic · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hereditary Angioedema
- Interventions
- KVD900 150 mg, KVD900 300 mg, KVD900 600 mg
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 7 more